Ligand discrimination in immune cells: Signal processing insights into immune dysfunction in ER+ breast cancer
Fig 5
JAK1/2 inhibition induces error rates and reduces SNR in healthy donors to levels comparable to breast cancer.
A. Immune cell subtypes for ER+ breast cancer samples (blue), healthy donors (grey) and a subset of 10 healthy donor samples also treated with ruxolitinib (red). Signal detection error rates are increased, and signal fidelity is decreased in all cell subtypes except for the error rate in naïve CD4 + T cells. B. Plotting the 10 samples treated with ruxolitinib on the same SNR- axes reveal relative error and signal fidelity characteristics. C. Comparisons of SNR and error rates for all cell subtypes in BC, HD, and HD + rux, and D. comparison of HD and HD + rux (unpaired t-tests adjusted for multiple comparisons,
). For illustration in the bar graphs, samples with
have
.